Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 214.32M P/E - EPS this Y 42.00% Ern Qtrly Grth -
Income -76.24M Forward P/E -4.12 EPS next Y -4.60% 50D Avg Chg 11.00%
Sales 70.14M PEG -0.30 EPS past 5Y - 200D Avg Chg -28.00%
Dividend N/A Price/Book 1.70 EPS next 5Y 15.00% 52W High Chg -65.00%
Recommedations 1.70 Quick Ratio 2.37 Shares Outstanding 70.30M 52W Low Chg 47.00%
Insider Own 3.22% ROA -17.70% Shares Float 63.61M Beta 2.03
Inst Own 82.73% ROE -65.89% Shares Shorted/Prior 2.37M/2.29M Price 3.21
Gross Margin -2.21% Profit Margin -108.69% Avg. Volume 1,029,203 Target Price 6.57
Oper. Margin 1.06% Earnings Date May 2 Volume 735,662 Change -2.73%
About Codexis, Inc.

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Codexis, Inc. News
04/18/24 Codexis to Report First Quarter 2024 Financial Results on May 2
04/11/24 Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board
03/30/24 Favourable Signals For Codexis: Numerous Insiders Acquired Stock
02/29/24 Codexis, Inc. (NASDAQ:CDXS) Q4 2023 Earnings Call Transcript
02/29/24 Q4 2023 Codexis Inc Earnings Call
02/28/24 Codexis (CDXS) Tops Q4 Earnings and Revenue Estimates
02/28/24 Codexis Inc (CDXS) Reports Fiscal Year 2023 Financial Results
02/28/24 Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results
02/26/24 Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche
02/26/24 Codexis to Participate in TD Cowen 44th Annual Health Care Conference
02/20/24 Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board
02/14/24 Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28
02/13/24 Codexis Secures $40 Million in Strategic Financing Deal with Innovatus Capital Partners to Further Strengthen Cash Position Ahead of Key Milestones
02/01/24 seqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General Meeting
01/14/24 The past three years for Codexis (NASDAQ:CDXS) investors has not been profitable
01/08/24 Baillie Gifford Trims Position in Codexis Inc
12/27/23 Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108
12/18/23 Codexis, Inc. (NASDAQ:CDXS) Stock Rockets 41% But Many Are Still Ignoring The Company
12/15/23 Is It Time To Consider Buying Codexis, Inc. (NASDAQ:CDXS)?
12/13/23 Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA Polymerase
CDXS Chatroom

User Image valueforme Posted - 4 days ago

$CDXS The proxy statement will likely be submitted by next weekend. Current Class II directors are Jennifer Aaker and Esther Martinborough. Aaker expressed her intention not to stand for reelection, which is good, we don't need diversity board members that have no clue about biotech. I wish Dilly to bring someone like Aldevron CEO Jennifer Meade as a board member nominee. Let's see.

User Image Stock_Titan Posted - 6 days ago

$CDXS Codexis to Report First Quarter 2024 Financial Results on May 2 https://www.stocktitan.net/news/CDXS/codexis-to-report-first-quarter-2024-financial-results-on-may-i91fwngwxpuf.html

User Image valueforme Posted - 1 week ago

$CDXS Just a reminder to everyone that last summer Cathie sold ARK position in Codexis. This is when I started to buy. And keep buying and solid science and seasoned management is key. She seems to be enjoying her losses in $DNA and especially in $PACB . You've heard of Inverse Kramer before, right? Inverse ARK is also a thing. Cheers.

User Image BeefStewart Posted - 1 week ago

$CDXS

User Image ThomasArchibald Posted - 1 week ago

$CDXS All of Biotech peaked late February. This truly is a rate cut story and it really looks like we’ll get none this year based off inflation numbers. That said, it’s down 42% from its peak, we should see a rebound soon. Key word: Should.

User Image valueforme Posted - 1 week ago

$CDXS No idea what kind of games are going on, but I'm buying more this week then

User Image valueforme Posted - 1 week ago

$CDXS If anyone has AAAS membership (I don't) - this article seems to be worth reading https://www.science.org/doi/10.1126/science.adl4015

User Image Aigner_Andreas Posted - 1 week ago

TD BUY $CDXS at 2.87, Supp 2.87 Resis 3.51 R22 HiLo 43% T1Y 18 buy 1.6 DIV N/A #Codexis In #stocks #trading #finance #market

User Image TheHowlingMadness Posted - 1 week ago

$CDXS what an embarrassment.

User Image nastento Posted - 1 week ago

$CDXS under 3 lol

User Image valueforme Posted - 1 week ago

$CDXS Added more before upcoming catalysts

User Image TheHowlingMadness Posted - 2 weeks ago

$CDXS

User Image valueforme Posted - 2 weeks ago

$CDXS TIDES USA is getting closer, folks. Tuesday, May 14, 2024. 12:30 Enzymatic Oligonucleotide Synthesis Process Flow and Substance Impurity Profile Derek Gauntlett, Director, Process Chemistry, Nucleic Acid Development and Manufacturing, Codexis

User Image ThomasArchibald Posted - 3 weeks ago

$CDXS Quiet in here

User Image valueforme Posted - 3 weeks ago

I enjoyed how Maraganore trolled DNA editing folks today. siRNA / ADAR for the future $CDXS $WVE $PRQR https://twitter.com/JMaraganore/status/1775212882810020299?t=FXQAMkMWrzHB3K0RRQdilg&s=19

User Image valueforme Posted - 03/30/24

$CDXS 1 year old, but still super relevant article to understand why siRNA manufacturing innovations is a big deal https://cen.acs.org/business/outsourcing/Drug-services-providers-gird-oligonucleotide/101/i13 Dilly keeps saying that current approaches won't scale Codexis is creating a bridge between the past and the future in the form of double-stranded RNA (dsRNA) ligase (a.k.a ecoRNA), and also working on the future itself - ECO Synthesis Manufacturing Platform.

User Image Turkeycock Posted - 03/28/24

$CDXS

User Image valueforme Posted - 03/27/24

$CDXS A week of staying in a very tight channel. What's next?

User Image Aigner_Andreas Posted - 03/27/24

TF SELL $CDXS at 3.45 : 3.49 MicroCap 66% Shp 1.04 S 4.99 N 0.73 RSI 49.32% SRSI 37.84% ADXR 23.99 #stocks #trading #finance #market

User Image Aigner_Andreas Posted - 1 month ago

TF SELL $CDXS at 3.27 : 3.31 MicroCap 60% Shp 0.97 S 3.03 N 0.84 RSI 48.67% SRSI 13.69% ADXR 24.17 #stocks #trading #finance #market

User Image TheHowlingMadness Posted - 1 month ago

$CDXS here we go

User Image nastento Posted - 1 month ago

$CDXS crazy how parallel this trades with the etf. Only 20k shares traded and we get these gains

User Image StupediaTrades Posted - 1 month ago

$CDXS Sweet

User Image TheHowlingMadness Posted - 1 month ago

$CDXS

User Image Lokmyster69 Posted - 1 month ago

$CDXS Picked up a couple hunderd more shares this morning 🦾 Looking for this to double digit in the near future

User Image xbizo Posted - 1 month ago

$CDXS I like to invest based upon long term targets. I figure $1B in revenue for 2030, but am I underestimating the potential here?

User Image valueforme Posted - 1 month ago

$CDXS "We built ourselves the runway to the end of 2026, by which time we think we should be healthily cash flow positive. Now we then did a debt financing with Innovatus to both give us more cushion on our cash runway, most of that debt is going to sit on the balance sheet and giving us more wiggle room, but also allocating $10M to scaling up the Innovation Lab. So the way we see the cadence is very soon from now, we expect to ink our first commercial customer on the ligase platform. We come to the middle of the year, the TIDES conference here in Boston. We're showing full length siRNA. We expect around that time to sign our first validating partnership in terms of a technical collaborator, one of those CDMOs I was talking about. Then we start signing up in the second half of the year, small companies working wanting to work at a GMP level. "

User Image StupediaTrades Posted - 1 month ago

$CDXS Hidden in plain sight .

User Image valueforme Posted - 1 month ago

$CDXS Added a lot this morning.

User Image BeefStewart Posted - 1 month ago

$CDXS nearly back to where it was a month ago...

Analyst Ratings
Benchmark Buy Feb 29, 24
Benchmark Hold Nov 7, 23
Piper Sandler Overweight Nov 6, 23
Benchmark Buy Sep 1, 23
Stifel Buy Aug 14, 23
Stephens & Co. Overweight Jul 21, 23
Benchmark Buy May 9, 23
HC Wainwright & Co. Neutral May 9, 23
Piper Sandler Overweight Apr 17, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Dorgan Byron L Director Director Nov 15 Sell 2.1084 20,000 42,168 193,461 11/17/23
Ryali Sriram Chief Financial Offi.. Chief Financial Officer Sep 08 Buy 1.7044 11,650 19,856 123,441 09/12/23
Norrett Kevin Chief Operating Offi.. Chief Operating Officer Sep 11 Buy 1.7199 9,000 15,479 98,102 09/12/23
Fitzgerald Margaret Nell See Remarks See Remarks Sep 08 Buy 1.6955 11,834 20,065 81,420 09/12/23
DILLY STEPHEN GEORGE See Remarks See Remarks Sep 08 Buy 1.7263 58,479 100,952 438,878 09/12/23
NICOLS JOHN J Director Director Apr 17 Sell 4.19 71,428 299,283 783,965 04/19/23
NICOLS JOHN J Director Director Apr 17 Option 1.97 71,428 140,713 819,679 04/19/23
NICOLS JOHN J Director Director Mar 15 Sell 4.1 71,428 292,855 783,965 03/17/23
NICOLS JOHN J Director Director Mar 15 Option 1.97 71,428 140,713 819,679 03/17/23
Norrett Kevin Chief Operating Offi.. Chief Operating Officer Feb 08 Sell 4.58 16,854 77,191 89,102 03/09/23
DILLY STEPHEN GEORGE See Remarks See Remarks Feb 08 Sell 4.58 55,075 252,244 380,399 03/09/23
Fitzgerald Margaret Nell See remarks See remarks Feb 08 Sell 4.58 15,686 71,842 69,586 03/09/23
NICOLS JOHN J President and CEO President and CEO Mar 09 Option 2.32 77,000 178,640 1,061,179 03/11/22
NICOLS JOHN J President and CEO President and CEO Mar 09 Sell 19.11 77,000 1,471,470 1,022,679 03/11/22
Dorgan Byron L Director Director Jan 21 Option 10.63 50,000 531,500 187,790 01/21/21
Dorgan Byron L Director Director Jan 21 Sell 25.96 50,000 1,298,000 162,790 01/21/21